Q-omics provides the consensus-scored SC4MOP profile across patient tissues and cancer cell-line models. SC4MOP expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SC4MOP is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, SC4MOP RNA expression shows 5,562 significant gene co-expression associations, with the highest sampling consensus in SKCM. Together, these results highlight KIRC, BRCA, and SKCM as cancer lineages where SC4MOP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SC4MOP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SC4MOP survival associations across molecular data types. SC4MOP RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SC4MOP RNA expression–survival associations across cancer types. High SC4MOP expression shows unfavorable associations in KIRC, UCS, LIHC, LUAD, TGCT and PCPG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SC4MOP RNA expression.
This table summarizes SC4MOP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SC4MOP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SC4MOP shows higher tumor expression in BRCA, COAD and LIHC. The BRCA box plot shows higher SC4MOP RNA expression in tumor versus normal tissue (log2 FC = +0.025, t-test p = .007).
This table shows molecular features associated with SC4MOP in patient tissues and cancer cell lines. In patient samples, SC4MOP shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
